[DOI] [PubMed] [Google Scholar] 489.Major J.M., Laughlin G.A., Kritz-Silverstein D., Wingard D.L., Barrett-Connor E
Orforglipron (LY3502970), a novel, oral nonpeptide glucagonlike peptide1 receptor agonist: a Phase 1a, blinded, placebocontrolled, randomized, singleand multipleascendingdose study in healthy participants
GLP-1 receptor agonistswhich are currently FDA-approved for people who are obese (a BMI of 30 or greater), have type 2 diabetes, or are overweight (a BMI of at least 27) and have cardiovascular disease or other risk factorsare emerging as a promising non-hormonal option for cardiometabolic protection during menopause
Browse berberine, mitochondrial blends, and professional-grade fiber formulas in your DSS dispensary or contact us to build a personalized protocol for your patients
Current product details, pricing, and terms can be confirmed by viewing the current GLPro offer (official GLPro page)
And that's totally understandable - it's a personal decision that you'll need to make with your healthcare team